SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

Home・Listă Acțiuni・Galapagos NV

Galapagos NV

Închisă

SectorSănătate

23.52 -0.84

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

23.32

Maxim

23.62

Indicatori cheie
By Trading Economics
Venit	-769M 14M
Vânzări	-894M 6.5M
P/E Medie Sector	3.182 51.415
EPS	11.9
Marjă de profit	214.257
Angajați	704
EBITDA	-813M -65M

Recomandări
By TipRanks
Recomandări	Vânzare
Prognoză pe 12 luni	+7.35% upside

Dividende
By Dow Jones
Următoarele câștiguri	10 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-41M 1.6B
Deschiderea anterioară	24.36
Închiderea anterioară	23.52

Sentimentul știrilor

By Acuity

40%

60%

127 / 345 Clasament în Healthcare

Galapagos NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

24 mar. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

24 mar. 2026, 14:25 UTC

Achiziții, Fuziuni, Preluări

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

24 mar. 2026, 13:35 UTC

Achiziții, Fuziuni, Preluări

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

24 mar. 2026, 12:03 UTC

Achiziții, Fuziuni, Preluări

Gilead to Buy Ouro Medicines for $2.2 Billion. 'Immune Reset' Is Key to Future Gains. -- Barrons.com

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

Comparație

Modificare preț

Galapagos NV Așteptări

Obiectiv de preț

By TipRanks

7.35% sus

Prognoză pe 12 luni

Medie 25.85 EUR 7.35%

Maxim 30 EUR

Minim 22 EUR

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGalapagos NV - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Vânzare

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Galapagos NV - Dist în ultimele 3 luni.

Sentiment

By Acuity

127 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.